Inhibition of EBV-Induced Lymphoproliferation by CD4+ T Cells Specific for an MHC Class II Promiscuous Epitope1

Posttransplant lymphoproliferative disorder (PTLD) and B cell lymphomas induced by EBV continue to be a major life-threatening complication in transplant patients. The establishment and enhancement of T cell immunity to EBV before transplantation and immunosuppressive therapy could help diminish these complications, but the lack of an effective vaccine has limited this prophylactic approach. We describe here the identification of a peptide epitope from the EBV EBNA2 Ag that is capable of inducing in vitro CD4+ T cell responses that inhibit the EBV-mediated B lymphocyte proliferation associated with PTLD. Most significantly, T cell responses to the EBNA2 epitope were found to be restricted by numerous MHC class II alleles (DR1, DR7, DR16, DR52, DQ2, and DQ7), indicating that this peptide is highly promiscuous and would be recognized by a large proportion (>50%) of the general population. These results are relevant for the design of a simple, inexpensive and widely applicable peptide-based vaccine to prevent PTLD in solid organ transplant patients.

[1]  P. Erb,et al.  Fas antigen is the major target molecule for CD4+ T cell-mediated cytotoxicity. , 1994, Journal of immunology.

[2]  P. Erb,et al.  Mechanism and Biological Significance of CD4‐mediated Cytotoxicity , 1995, Immunological reviews.

[3]  Jaap M Middeldorp,et al.  Treatment of posttransplant lymphoproliferative disease with rituximab: the remission, the relapse, and the complication. , 2002, Transplantation.

[4]  M F del Guercio,et al.  Several common HLA-DR types share largely overlapping peptide binding repertoires. , 1998, Journal of immunology.

[5]  D. Srivastava,et al.  Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. , 1998, Blood.

[6]  E. Appella,et al.  Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen. , 2000, Cancer research.

[7]  E. Kieff,et al.  An Epstein-Barr virus nuclear protein 2 domain essential for transformation is a direct transcriptional activator , 1991, Journal of virology.

[8]  E. Celis,et al.  Use of two predictive algorithms of the world wide web for the identification of tumor-reactive T-cell epitopes. , 2000, Cancer research.

[9]  A. Fischer,et al.  Chimaeric anti‐CD20 monoclonal antibody (rituximab) in post‐transplant B‐lymphoproliferative disorder following stem cell transplantation in children , 2001, British journal of haematology.

[10]  E. Kieff,et al.  Epstein-barr virus-induced posttransplant lymphoproliferative disorders , 1999 .

[11]  S. Burrows,et al.  Vaccine strategies against Epstein‐Barr virus‐associated diseases: lessons from studies on cytotoxic T‐cell‐mediated immune regulation , 1999, Immunological reviews.

[12]  P. Cresswell,et al.  Class I processing-defective Burkitt's lymphoma cells are recognized efficiently by CD4+ EBV-specific CTLs. , 1997, Journal of immunology.

[13]  D. Rowe,et al.  Epstein-Barr virus immortalization and latency. , 1999, Frontiers in bioscience : a journal and virtual library.

[14]  Antonio Lanzavecchia,et al.  Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells , 1989, European journal of immunology.

[15]  A. Vitiello,et al.  Design and testing of peptide-based cytotoxic T-cell-mediated immunotherapeutics to treat infectious diseases and cancer. , 1995, Pharmaceutical biotechnology.

[16]  B. Griffin,et al.  Epstein-Barr virus latent gene expression during the initiation of B cell immortalization. , 1989, The Journal of general virology.

[17]  E. Kieff,et al.  Genetic and biochemical evidence that EBNA 2 interaction with a 63-kDa cellular GTG-binding protein is essential for B lymphocyte growth transformation by EBV. , 1994, Virology.

[18]  H. Heslop,et al.  Adoptive cellular immunotherapy for EBV lymphoproliferative disease. , 1997, Immunological reviews.

[19]  N. Sigal,et al.  Cyclosporin A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction. , 1992, Annual review of immunology.

[20]  M. Nalesnik.  Clinical and pathological features of post-transplant lymphoproliferative disorders (PTLD) , 2004, Springer Seminars in Immunopathology.

[21]  E. Kieff.  Epstein-Barr virus and its replication , 1996 .

[22]  E. Celis,et al.  Identification of helper T-cell epitopes that encompass or lie proximal to cytotoxic T-cell epitopes in the gp100 melanoma tumor antigen. , 2001, Cancer research.

[23]  E. Kieff,et al.  Early events in Epstein-Barr virus infection of human B lymphocytes. , 1991, Virology.

[24]  E. Kieff,et al.  Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. , 1999, Transplantation.

[25]  A. Trzeciak,et al.  A malaria T-cell epitope recognized in association with most mouse and human MHC class II molecules , 1988, Nature.

[26]  T. Habermann,et al.  Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations. , 1995, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[27]  Zhensheng Liu,et al.  Generation of EBV-Specific CD4+ Cytotoxic T Cells from Virus Naive Individuals1 , 2002, The Journal of Immunology.

[28]  E. Appella,et al.  Tumor-reactive T helper lymphocytes recognize a promiscuous MAGE-A3 epitope presented by various major histocompatibility complex class II alleles. , 2001, Cancer research.

[29]  S. Burrows,et al.  Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated diseases. , 2000, Annual review of microbiology.

[30]  S. Nikiforow,et al.  CD4+ T-Cell Effectors Inhibit Epstein-Barr Virus-Induced B-Cell Proliferation , 2001, Journal of Virology.

[31]  D. Moss,et al.  Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. , 1997, Annual review of immunology.

[32]  R. Ambinder,et al.  The biology of Epstein–Barr virus in post‐transplant lymphoproliferative disease , 1999, Transplant infectious disease : an official journal of the Transplantation Society.

[33]  D. Thorley-Lawson,et al.  EBV persistence in memory B cells in vivo. , 1998, Immunity.

[34]  F. Marincola,et al.  Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma , 1998, Nature Medicine.

[35]  C Oseroff,et al.  Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. , 1994, Immunity.

[36]  R. Bright.  Peptide-Based Cancer Vaccines , 2002, Leukemia.

[37]  H. Heslop,et al.  Adoptive cellular immunotherapy for EBV lymphoproliferative diseases , 1997 .

[38]  V. Engelhard,et al.  Identification of a population of CD4+ CTL that utilizes a perforin- rather than a Fas ligand-dependent cytotoxic mechanism. , 1996, Journal of immunology.

[39]  D. Crawford,et al.  The role of EBV in post-transplant malignancies: a review , 2000, Journal of clinical pathology.

[40]  L. Olson,et al.  Treatment of post-transplant lymphoproliferative disorder with monoclonal CD20 antibody (rituximab) after heart transplantation. , 2001, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[41]  B. Hemmer,et al.  Human autoreactive CD4+ T cell clones use perforin- or Fas/Fas ligand-mediated pathways for target cell lysis. , 1997, Journal of immunology.

[42]  N. Cascinelli,et al.  Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGES‐3 , 1995, International journal of cancer.